Investigation of Anticancer Effects of Alpha-synuclein in Lung Cancer

Lung cancer, especially non-small cell lung cancer (NSCLC) poses a global health challenge with a low survival rate. Alpha-synuclein (SNCA), the protein that aggregates to form Lewy bodies in Parkinson’s disease, is reported to be downregulated in lung cancer. However, its role in anticancer treatment remains unclear. Thus, this study explores the biological responses of SNCA overexpression in NSCLC and identifies the key proteins and the signalling pathways modulated by SNCA overexpression. These research findings suggest that SNCA may function as a tumour suppressor, offering the potential for more effective therapeutic responses against NSCLC.